NASDAQ:ALT 25 November 2025

Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants

Altimmune stock gained roughly 10% in premarket trading on Tuesday. The company’s Phase 2 RECLAIM study showed pemvidutide achieved its primary endpoint. U.S. markets had not opened at the time of reporting.

28 July 2026

NASDAQ:ALT·Pharmaceuticals·Stock Market

Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus

Altimmune shares ended Friday’s session at $5.60, roughly 10% higher, with the stock fluctuating between $5.00 and $5.65 during the day. Trading volume hit around 6.3 million shares.

31 January 2026

NASDAQ:ALT·Stock Market

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune, Inc. is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a high-stakes clinical update is expected before year-end, leadership is changing hands, and Wall Street price targets remain dramatically spread out.

17 December 2025

NASDAQ:ALT·Stock Market

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide and a capital-raising backdrop that can quickly change the stock's risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets, and impending data readouts are all influencing sentiment.

12 December 2025

Financial Forecasts·NASDAQ:ALT·Stock Market

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune, Inc. has become a tightly wound biotech story heading into year‑end 2025. The small‑cap developer of liver and metabolic drugs is changing its CEO just weeks before a pivotal 48‑week readout in its lead MASH trial, while Wall Street models still point to triple‑digit upside from today’s share price.

9 December 2025

Investment Opportunities·NASDAQ:ALT

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune Inc. continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8 and $5.2 per share. INDmoney

25 November 2025

NASDAQ:ALT·Pharmaceutical Industry·Stock Market

NASDAQ:ALT 25 November 2025 - 28 July 2026

Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants

Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

TechStock² Updates

Airbnb (NASDAQ:ABNB) Shares Rise on AI Cost-Cutting and Higher Bookings

Joby Aviation (NYSE:JOBY) Rises in Premarket as Blade Delivers 94% of Revenue

Nasdaq Futures Rise as US Jobs Data Dents Fed Rate Hike Expectations

Oklo (NYSE:OKLO) achieves reactor criticality; $4.2 billion valuation requires commercial validation

Plug Power (NASDAQ:PLUG) Confronts $471 Million Revenue Challenge in Second Half

Top Stock Picks

Constellation Energy

AerCap

Walt Disney

AIG

Cheniere Energy

Live updates

Investment Disclaimer